Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zhejiang Medicine Reports Positive Data for HER2 Treatment in Pretreated Patients

publication date: Dec 12, 2019

Zhejiang Medicine and its majority owned subsidiary, NovoCodex, announced positive early results from a China Phase I trial of an anti-HER2 ADC in heavily pretreated patients with metastatic HER2 positive breast cancer. At the highest dose tested before data cutoff, ARX788 achieved a 63% overall response rate. The candidate targets human epidermal growth factor receptor 2 and causes apoptosis. ARX788 was developed by Ambrx of San Diego and in-licensed by NovoCodex, which is in charge of Phase I development. In return, NovoCodex is eligible to receive a royalty on non-China revenues. More details...

Stock Symbol: (SHA: 600216)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.